Gravity Analytica

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024

SNDX 10.29.2024

SERA-AI Powered Highlights

Drug:SNDX-001 revumenib

Drug:SNDX-002 NiktimvoTM (axatilimab-csfr)

Date of Upcoming Event:2024-11-05

Name of Upcoming Event:Q3 2024 Earnings Call

Full Press Release SEC Filings Our SNDX Tweets

About Gravity Analytica

Recent Filings

WALTHAM, Mass.,Oct. 29, 2024/PRNewswire/ --Syndax Pharmaceuticals(Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2024 financial results and provide a business update onTuesday, November 5, 2024.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at4:30 p.m. ETonTuesday, November 5, 2024to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through theEvents & Presentations pagein the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax3Q24Domestic Dial-in Number: 800-590-8290International Dial-in Number: 240-690-8800Live webcast:https://www.veracast.com/webcasts/syndax/events/SNDX3Q24.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website atwww.syndax.comapproximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo^TM(axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visitwww.syndax.com/or follow the Company onX (formerly Twitter)andLinkedIn.

Syndax Contact

Sharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-third-quarter-2024-financial-results-and-host-conference-call-and-webcast-on-november-5-2024-302286420.html

SOURCESyndax Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com